James Blachly
Overview
Explore the profile of James Blachly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grever M, Andritsos L, Anghelina M, Arons E, Banerji V, Barrientos J, et al.
Leukemia
. 2024 Jun;
38(7):1642-1644.
PMID: 38851853
No abstract available.
2.
Marr A, Halpin M, Corbin D, Asemelash Y, Sher S, Gordon B, et al.
Exp Hematol Oncol
. 2024 Mar;
13(1):27.
PMID: 38438856
Acute myeloid leukemia (AML) is a highly aggressive hematologic cancer with poor survival across a broad range of molecular subtypes. Development of efficacious and well-tolerable therapies encompassing the range of...
3.
Woyach J, Perez Burbano G, Ruppert A, Miller C, Heerema N, Zhao W, et al.
Blood
. 2024 Jan;
143(16):1616-1627.
PMID: 38215395
A041202 (NCT01886872) is a phase 3 study comparing bendamustine plus rituximab (BR) with ibrutinib and the combination of ibrutinib plus rituximab (IR) in previously untreated older patients with chronic lymphocytic...
4.
Sher S, Whipp E, Walker J, Zhang P, Beaver L, Williams K, et al.
Leukemia
. 2022 Nov;
37(2):326-338.
PMID: 36376377
Chronic lymphocytic leukemia (CLL) is effectively treated with targeted therapies including Bruton tyrosine kinase inhibitors and BCL2 antagonists. When these become ineffective, treatment options are limited. Positive transcription elongation factor...
5.
Lai T, Ozer H, Gasparini P, Nigita G, Distefano R, Yu L, et al.
Blood Adv
. 2022 Oct;
7(12):2897-2911.
PMID: 36287107
Chronic lymphocytic leukemia (CLL) is a quiescent B-cell malignancy that depends on transcriptional dysregulation for survival. The histone deacetylases are transcriptional regulators whose role within the regulatory chromatin and consequence...
6.
Ozga M, Blachly J, Eisfeld A, Grieselhuber N, Larkin K, Walker A, et al.
Am J Hematol
. 2021 Mar;
96(7):E223-E225.
PMID: 33761147
No abstract available.
7.
Saygin C, Grieselhuber N, Blachly J, Byrd J, Vasu S, Larkin K, et al.
Leuk Res
. 2020 Jan;
89:106297.
PMID: 31935625
No abstract available.
8.
Jeon J, Zhao Q, Buelow D, Phelps M, Walker A, Mims A, et al.
Invest New Drugs
. 2019 May;
38(2):340-349.
PMID: 31102119
Activating FLT3 internal tandem duplication (FLT3-ITD) mutations in acute myeloid leukemia (AML) associate with inferior outcomes. We determined that pacritinib, a JAK2/FLT3 inhibitor, has in vitro activity against FLT3-ITD and...
9.
Mims A, Mishra A, Orwick S, Blachly J, Klisovic R, Garzon R, et al.
Haematologica
. 2018 Mar;
103(6):982-987.
PMID: 29567781
partial tandem duplication occurs in approximately 5-10% of patients with acute myeloid leukemia and is associated with adverse prognosis. wild type is epigenetically silenced in partial tandem duplication; re-expression can...
10.
Markowitz J, Mal T, Yuan C, Courtney N, Patel M, Stiff A, et al.
Protein Sci
. 2016 Mar;
25(5):1069-74.
PMID: 26947772
It was recently discovered that the NRAS isoform 5 (20 amino acids) is expressed in melanoma and results in a more aggressive cell phenotype. This novel isoform is responsible for...